GeneProt and Lundbeck Collaborate in CNS Proteomics

23-Apr-2004
Geneva Switzerland. GeneProt Inc. announced that it has established a collaboration with H. Lundbeck A/S, a leading pharmaceutical company in the area of diseases of the central nervous system (CNS). The aim of the collaboration is to study the proteomics of bio-fluid samples taken from a rodent model of CNS disease, where GeneProt will apply its MicroProt(r) process to the samples. Lundbeck will have exclusive right to commercialize results generated, although further financial details were not disclosed. "We are pleased to collaborate with Lundbeck and continue to exploit our MicroProt(r) discovery platform in the important area of CNS disorders" said Bertrand Damour, GeneProt's President and CEO. "The combination of GeneProt's protein discovery and synthesis capability with Lundbeck's knowledge and expertise in developing animal models of CNS disorders will allow us to capitalize on comparisons of plasma proteomes and gene expression profiling" said Peter Hongaard Andersen, Head of Research at Lundbeck.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances